DelveInsight’s, “Janus kinase inhibitors Competitive landscape 2024” report provides comprehensive insights about 40+ Janus kinase Inhibitors Companies and 45+ drugs in Janus kinase inhibitors Competitive landscape. It covers the Janus kinase Inhibitors therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Janus kinase Inhibitors Report

• DelveInsight’s Janus kinase Inhibitors report depicts a robust space with 40+ Janus kinase Inhibitors companies working to develop 45+ pipeline therapies for Janus kinase Inhibitors treatment.
• The leading Janus kinase Inhibitors Companies working in the market include Pfizer, Sierra Oncology, Theravance Biopharma, Dizal Pharmaceutical, Aclaris Therapeutics, Celon Pharma, Incyte Corporation, AbbVie, Galapagos, Gilead Sciences, Reistone Biopharma, Jiangsu Hengrui Medicine Co., MaxiNovel Pharmaceuticals, and others.
• Promising Janus kinase Inhibitors Therapies in the various stages of development include KPL-404, Baricitinib, Ruxolitinib, GSK3196165 (Otilimab), Sarilumab, csDMARDs, AZD4205, TD-0903, TL-895, and others.
• December 2023: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) announced a study of Phase 2 clinical trials for Abrocitinib 200 MG Oral Tablet and Ritlecitinib. A multi-center, placebo-controlled, double blind, 1:1:1 randomized control clinical trial testing two different JAK Inhibitors abrocitnib, ritlecitinib, and placebo in subjects with recent onset Stage 3 Type 1 Diabetes within 100 days of diagnosis.
• December 2023: Celgene announced a study of Phase 3 clinical trials for ACE-536. The purpose of this Phase 3 study is to evaluate the efficacy and safety of Luspatercept compared with placebo in subjects with myeloproliferative neoplasm (MPN)-associated Myelofibrosis (MF) and anemia on concomitant Janus kinase 2 (JAK2) inhibitor therapy and who require red blood cell count (RBC) transfusions.

 

Request a sample and discover the recent advances in Janus kinase Inhibitors Drugs @ Janus kinase Inhibitors Competitive Landscape Report

 

The Janus kinase Inhibitors report provides in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition – deals values trends. The sub-segmentation is described in the Janus kinase Inhibitors report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form.

 

Janus kinase Inhibitors Overview

Janus kinase (JAK) inhibitors are small molecules approximately 400 Da that could be administrated as oral medicines. JAKs are phosphotransferases that bind to the intracellular domains of cytokine receptors and transmit signals to activate immune responses. The family of cytokines that signal via JAKs includes many interleukins, interferons, colony stimulating factors and hormone like cytokines (such as erythropoietin).

 

Find out more about Janus kinase Inhibitors Analytical Perspective: In-depth Commercial Assessment @ Janus kinase Inhibitors Collaboration Analysis by Companies

 

Janus kinase Inhibitors Companies and Therapies

• Eli Lilly and Company: OLUMIANT
• AbbVie: RINVOQ
• Galapagos: Filgotinib
• Incyte: Povorcitinib
• MaxiNovel Pharmaceuticals: MAX-40279/MAX-40070

 

Janus kinase Inhibitors Competitive Landscape: Analytical Perspective

The Janus kinase Inhibitors report comprises of comparative assessment of Companies (by therapy, development stage, and technology).

 

JAK Inhibitors Report Assessment

• Janus kinase Inhibitors Company Analysis
• Janus kinase Inhibitors Therapeutic Assessment
• Janus kinase Inhibitors Pipeline Assessment
• Inactive drugs assessment
• Janus kinase Inhibitors Unmet Needs

 

Learn more about the emerging Janus kinase Inhibitors Competitive Landscape @ Janus kinase Inhibitors Market Drivers and Barriers, Unmet Needs

 

Scope of the Janus Kinase Inhibitors Report

• Coverage- Global
• Janus kinase Inhibitors Companies- Pfizer, Sierra Oncology, Theravance Biopharma, Dizal Pharmaceutical, Aclaris Therapeutics, Celon Pharma, Incyte Corporation, AbbVie, Galapagos, Gilead Sciences, Reistone Biopharma, Jiangsu Hengrui Medicine Co., MaxiNovel Pharmaceuticals, and others.
• Janus kinase Inhibitors Therapies- KPL-404, Baricitinib, Ruxolitinib, GSK3196165 (Otilimab), Sarilumab, csDMARDs, AZD4205, TD-0903, TL-895, and others.
• Janus kinase Inhibitors Therapeutics Assessment- Product Type, Stage and Product Type, Route of Administration, Stage and Route of Administration, Molecule Type, Stage and Molecule Type

 

Dive deep into rich insights for new drugs for Janus kinase Inhibitors Product Developmental Activities, Visit @ Janus kinase Inhibitors Research and Development Activities

 

Table of Content

1. Introduction
2. Executive Summary
3. JAK inhibitors: Overview
4. JAK inhibitors -Analytical Perspective: In-depth Commercial Assessment
5. Competitive Landscape
6. Therapeutic Assessment
7. JAK inhibitors: Company and Product Profiles (Marketed Therapies)
8. Eli Lilly and Company
9. OLUMIANT
10. JAK inhibitors: Company and Product Profiles (Pipeline Therapies)
11. Late Stage Products (Phase III)
12. Galapagos
13. Filgotinib
14. Drug profiles in the detailed report…..
15. Mid Stage Products (Phase II)
16. MaxiNovel Pharmaceuticals
17. MAX-40279
18. Drug profiles in the detailed report…..
19. Early Stage Products (Phase I)
20. MaxiNovel Pharmaceuticals
21. MAX-40070
22. Drug profiles in the detailed report…..
23. Preclinical and Discovery Stage Products
24. Company Name
25. Product Name
26. Drug profiles in the detailed report…..
27. Inactive Products
28. JAK inhibitors- Unmet needs
29. JAK inhibitors – Market drivers and barriers
30. Appendix

 

For further information on the Janus kinase Inhibitors Report @ Janus kinase Inhibitors Preclinical and Discovery Stage Products

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services